Welcome to Pharmaxis

Pharmaxis is a specialist pharmaceutical company that researches, develops and commercialises new therapies for undertreated respiratory diseases.

Founded on an Australian discovery, Pharmaxis' products are now available worldwide.

Company Highlights

Asthma patients breathing easier

Asthma patients' breathing was improved by an outstanding 32-49% in Phase 2 clinical trials of Pharmaxis' new anti-inflammatory agent ASM8.

Results announced for second Phase 3 trial of Bronchitol in people with cystic fibrosis

Pharmaxis is pleased to announce top line results from the second large-scale global Phase 3 trial of Bronchitol in patients with cystic fibrosis.

PXS25 passes its first clinical hurdle

The first Phase 1 trial of Pharmaxis' new antifibrotic agent PXS25 has delivered encouraging results.

New factory fully operational

The new manufacturing plant in Rodborough Rd Frenchs Forest is now fully operational and the qualification work on the new equipment is essentially complete.